ArticleMolecular therapy : the journal of the American Society of Gene Therapy2020
miR-1293, a Candidate for miRNA-Based Cancer Therapeutics, Simultaneously Targets BRD4 and the DNA Repair Pathway.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- High-throughput 3D spheroid screens identify microRNA sensitizers for improved thermoradiotherapy in locally advanced cancers.Molecular therapy. Nucleic acids · 2025Article
- MiR-1293 modulates PPARGC1A to promote proliferation and metastasis of oral carcinoma cells.Journal of molecular histology · 2025Article
- TLR4 mediates lipotoxic β-cell dysfunction by inhibiting the TMEM24/PI3K/AKT pathway.Acta biochimica et biophysica Sinica · 2025Article
- BRD4 Degradation Enhanced Glioma Sensitivity to Temozolomide by Regulating Notch1 via Glu-Modified GSH-Responsive Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Diagnostic, prognostic, and therapeutic potential of exosomal microRNAs in renal cancer.Pharmacological reports : PR · 2024Review
- Application of Nanoparticles in the Diagnosis and Treatment of Colorectal Cancer.Anti-cancer agents in medicinal chemistry · 2024Review
- The antitumour efficacy of hesperidin vs. cisplatin against non-small lung cancer cells A549 and H460Contemporary oncology (Poznan, Poland) · 2024Article
- Small Non-Coding RNAs in Human Cancer.Genes · 2022Review
- Identification of the circRNA-miRNA-mRNA Prognostic Regulatory Network in Lung Adenocarcinoma.Genes · 2022Article
- Extracellular Vesicles-A New Potential Player in the Immunology of Renal Cell Carcinoma.Journal of personalized medicine · 2022Review
- Impact of Non-Coding RNAs on Chemotherapeutic Resistance in Oral Cancer.Biomolecules · 2022Review
- Host miRNA and immune cell interactions: relevance in nano-therapeutics for human health.Immunologic research · 2022Review
- The crosstalk between reactive oxygen species and noncoding RNAs: from cancer code to drug role.Molecular cancer · 2022Review
- Bioinformatics analysis of tumor-educated platelet microRNAs in patients with hepatocellular carcinoma.Bioscience reports · 2021Article
- Concurrent targeting of MAP3K3 and BRD4 byMolecular therapy. Nucleic acids · 2021Article
- Cancer-associated miRNAs and their therapeutic potential.Journal of human genetics · 2021Review
- Article
- Improving the Efficacy of EGFR Inhibitors by Topical Treatment of Cutaneous Squamous Cell Carcinoma withMolecular therapy oncolytics · 2020Article
- Circulating exosomal microRNAs as novel potential detection biomarkers in pancreatic cancer.Oncology letters · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BRD4, a member of the bromodomain and extra-terminal domain (BET) protein family, plays a role in the organization of super-enhancers and transcriptional activation of oncogenes in cancer and is recognized as a promising target for cancer therapy. microRNAs (miRNAs), endogenous small noncoding RNAs, cause mRNA degradation or inhibit protein translation of their target genes by binding to complementary sequences. miRNA mimics simultaneously targeting several tumor-promoting genes and BRD4 may be useful as therapeutic agents of tumor-suppressive miRNAs (TS-miRs) for cancer therapy. To investigate TS-miRs for the development of miRNA-based cancer therapeutics, we performed function-based screening in 10 cancer cell lines with a library containing 2,565 human miRNA mimics. Consequently, miR-1293, miR-876-3p, and miR-6571-5p were identified as TS-miRs targeting BRD4 in this screening. Notably, miR-1293 also suppressed DNA repair pathways by directly suppressing the DNA repair genes APEX1 (apurinic-apyrimidinic endonuclease 1), RPA1 (replication protein A1), and POLD4 (DNA polymerase delta 4, accessory subunit). Concurrent suppression of BRD4 and these DNA repair genes synergistically inhibited tumor cell growth in vitro. Furthermore, administration of miR-1293 suppressed in vivo tumor growth in a xenograft mouse model. These results suggest that miR-1293 is a candidate for the development of miRNA-based cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.